Literature DB >> 11149618

Identification of a novel deletion of the entire OCRL1 gene detected by FISH analysis in a family with Lowe syndrome.

J Peverall1, E Edkins, J Goldblatt, A Murch.   

Abstract

The oculocerebrorenal syndrome of Lowe (OCRL) is a rare X-linked multisystem disorder affecting the lens, kidney and brain. The gene involved (OCRL1) has been identified and is known to encode a phosphatidylinositol 4,5-bisphosphate 5-phosphatase. Mutations in OCRL1 have been shown to be causative of OCRL. To date, most of the mutations identified have consisted of simple or point mutations and there is one report of a 1.4-kb deletion. We investigated the OCRL1 gene in a male patient with OCRL by the polymerase chain reaction and found that the entire OCRL1 gene was deleted. Fluorescence in situ hybridisation analysis (FISH), with cosmid probes that span the entire OCRL1 gene, was used to confirm this deletion and subsequently identify it in the proband's mother. This is the first report of a whole gene deletion of OCRL1 and thus expands the range of mutations that give rise to OCRL. The use of the FISH technique facilitated carrier and prenatal testing for the deletion in the family.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11149618     DOI: 10.1034/j.1399-0004.2000.580609.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  6 in total

1.  A novel and de novo deletion in the OCRL1 gene associated with a severe form of Lowe syndrome.

Authors:  Ramón Peces; Carlos Peces; Erika de Sousa; Cristina Vega; Rafael Selgas; Julián Nevado
Journal:  Int Urol Nephrol       Date:  2012-07-21       Impact factor: 2.370

2.  Characterization of 28 novel patients expands the mutational and phenotypic spectrum of Lowe syndrome.

Authors:  Florian Recker; Marcin Zaniew; Detlef Böckenhauer; Nunzia Miglietti; Arend Bökenkamp; Anna Moczulska; Anna Rogowska-Kalisz; Guido Laube; Valerie Said-Conti; Belde Kasap-Demir; Anna Niemirska; Mieczysław Litwin; Grzegorz Siteń; Krystyna H Chrzanowska; Małgorzata Krajewska-Walasek; Sidharth K Sethi; Velibor Tasic; Franca Anglani; Maria Addis; Anna Wasilewska; Maria Szczepańska; Krzysztof Pawlaczyk; Przemysław Sikora; Michael Ludwig
Journal:  Pediatr Nephrol       Date:  2014-12-06       Impact factor: 3.714

3.  Exome-first approach identified a novel gloss deletion associated with Lowe syndrome.

Authors:  Miki Watanabe; Ryuji Nakagawa; Tomohiro Kohmoto; Takuya Naruto; Ken-Ichi Suga; Aya Goji; Hideaki Horikawa; Kiyoshi Masuda; Shoji Kagami; Issei Imoto
Journal:  Hum Genome Var       Date:  2016-11-10

4.  Ocular Pathology of Oculocerebrorenal Syndrome of Lowe: Novel Mutations and Genotype-Phenotype Analysis.

Authors:  Emilie Song; Na Luo; Jorge A Alvarado; Maria Lim; Cathleen Walnuss; Daniel Neely; Dan Spandau; Alireza Ghaffarieh; Yang Sun
Journal:  Sci Rep       Date:  2017-05-04       Impact factor: 4.379

5.  Modeling the neuropsychiatric manifestations of Lowe syndrome using induced pluripotent stem cells: defective F-actin polymerization and WAVE-1 expression in neuronal cells.

Authors:  Jesse Barnes; Franklin Salas; Ryan Mokhtari; Hedwig Dolstra; Erika Pedrosa; Herbert M Lachman
Journal:  Mol Autism       Date:  2018-08-15       Impact factor: 7.509

6.  Whole-genome sequencing revealed an interstitial deletion encompassing OCRL and SMARCA1 gene in a patient with Lowe syndrome.

Authors:  Bixia Zheng; Qiuxia Chen; Chunli Wang; Wei Zhou; Ying Chen; Guixia Ding; Zhanjun Jia; Aihua Zhang; SongMing Huang
Journal:  Mol Genet Genomic Med       Date:  2019-08-03       Impact factor: 2.183

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.